
Lansdowne et al. in £25m series-B for Genomics
Investment firm Lansdowne Partners has backed UK-based genetic data researcher Genomics.
US-based drug developer Vertex Pharmaceuticals led the funding round. Other participating investors included listed tech investor IP Group, asset managers Woodford Investment Management and Invesco Perpetual, Oxford University spinouts incubator Oxford Sciences Innovation, investment firm Lansdowne Partners and Tanarra.
With the new funding, Genomics will expand to enhance its database and to pursue opportunities that emerge in its market space.
Additionally, Genomics will use the fresh capital to collaborate with Vertex, in order to advance Vertex's efforts to develop transformative medicines for people with serious diseases.
Company
Founded in 2014 and headquartered in Oxford, Genomics is a genome analysis company. It has developed an analysis engine that uses genetics to understand human biology and the likely efficacy and safety of potential novel medicines. Genomics has a cross-disciplinary team of 40 people, primarily scientists and software engineers, with offices in Oxford and Cambridge.
People
Genomics – Peter Donnelly (founder, CEO).
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater